FDA Deems Adalimumab Biosimilar Cyltezo Interchangeable FDA Deems Adalimumab Biosimilar Cyltezo Interchangeable

The supplemental biologics license approval for Cyltezo makes the adalimumab biosimilar just the second biosimilar to be designated as interchangeable with its originator biologic product.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Gastroenterology News Source Type: news